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Abstract
Introduction. Gaucher disease (GD) is an infrequent progressive multisystem lysosomal storage disorder caused by the
deﬁcient activity of the lysosomal enzyme, glucocerebrosidase. A retrospective, single-center analysis of the clinical experience
concerning the use of miglustat (N-butyldeoxynojirimycin), an oral inhibitor of glucosylceramide synthase, in type 1 Gaucher
disease (GD1) was conducted to evaluate the efﬁcacy, adverse events (AE), and outcome of miglustat therapy.
Patients and methods. Six adult Caucasian patients with GD1 (two women and four men), aged 21–81 years (median age
59 years), were treated with miglustat between October 2005 and April 2011. All but one patient (83%) carried at least one
allele with c.1226A>G (N370S) mutation in the GBA1 gene.
Results. Weight loss, diarrhea, poor appetite, and tremor were frequently reported AE by the patients. All of them experienced
at least 2 AE, and three patients (50%) experienced at least 4 AE. Only two out of six patients (33%) have used miglustat longer
than 12 months, of which only one used it longer than 15 months.
Conclusions. The major obstacle to successful miglustat therapy in GD1 was the high proportion of patients discontinuing their
treatment due to the AE and the worsened quality of life. Further efforts are needed to improve tolerability of miglustat and, in
consequence, compliance of patients treated with this orphan drug.
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Introduction
Gaucher disease (GD) is an infrequent progressive
multisystem lysosomal storage disorder (LSD) caused
by the deﬁcient activity of the lysosomal enzyme,
glucocerebrosidase (GBA), arising from autosomal
recessive mutations in the GBA1 gene (1q21) (1).
There are more than 300 known mutations that can
causeGD, amongwhichthec.1226A>G (N370S)and
the c.1448T>C (L444P) mutations are the most
prevalent. Decreased GBA activity results in the accu-
mulation of glucosylceramide in cells of the monocyte-
macrophage system throughout the body (2,3). The
clinical presentation of GD is highly variable. Classi-
cally, three clinical types of GD are distinguished
according to the absence (type 1) or presence (types
2and3)ofneurologicalsymptomsandthedynamicsof
developing clinical signs. Thrombocytopenia, anemia,
hepatosplenomegaly, and bone manifestations are the
most typical signs of type 1 (GD1), the most prevalent
form of GD (3). GD can be found in all ethnic groups.
In Sweden, the overall prevalence of GD is approxi-
mately 1:170,000 individuals (unpublished own data),
and this ﬁgure is slightly lower than GD prevalence
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higher than in other Nordic countries (2,3).
Until 2010, two treatment options were available in
Sweden for patients with GD: enzyme replacement
therapy (ERT) with macrophage-targeted recombi-
nant glucocerebrosidase (Cerezyme
 
, Genzyme Cor-
poration, Cambridge, MA, USA), and substrate
reduction therapy (SRT) with miglustat (Zavesca
 
,
Actelion Pharmaceuticals, Allschwil, Switzerland).
ERT was introduced for treatment of GD in 1991,
and it is the standard of care for GD patients requiring
treatment (2). ERT quickly and effectively improves
hematological and visceral manifestations of GD,
although its action on skeletal GD manifestations is
slower, often taking many years before achieving
improvement (4–7). SRT with N-butyldeoxynojiri-
mycin (miglustat), a small iminosugar molecule,
reversibly inhibits glucosylceramide synthase, the
ceramide-speciﬁc glucosyltransferase that catalyzes
the ﬁrst committed step in glycosphingolipid synthe-
sis, and in this way reduces intracellular storage of
glucosylceramide (8). Miglustat is commercially
available for the treatment of mild to moderate
GD1 in the EU since 2002. Recent data conﬁrmed
miglustat efﬁcacy in the long-term maintenance ther-
apy of GD1 (9).
The purpose of our work was to evaluate retro-
spectively the efﬁcacy and adverse events (AE) of
miglustat therapy in adults with GD1 treated in the
clinical practice setting.
Patients and methods
There are currently 35 patients diagnosed with GD1 in
Sweden. Between 2002 and 2010, 12 adults with
GD1 were followed at Karolinska University Hospital
in Stockholm, Sweden. Of these, six (50%) patients
weretemporarilyorpermanentlytreatedwithmiglustat
and were included in this analysis.
In all studied patients, the diagnosis of GD was
conﬁrmed by a low activity of glucocerebrosi-
dase in peripheral blood leukocytes and increased
activity of plasma chitotriosidase at a reference
laboratory according to standard practice. Fur-
ther direct DNA sequencing performed at the
Academic Medical Center in Amsterdam, the Neth-
erlands, revealed mutations in the GBA1 gene in all
cases.
Patients received commercially available miglustat
capsules of 100 mg (Zavesca
 
, Actelion Pharma-
ceuticals) orally at a dose of 100 mg three times a
day (t.i.d.). Recommendations concerning the cor-
rect administration of miglustat and the implemen-
tation of a low-carbohydrate diet (especially during
the ﬁrst weeks of treatment) were provided to all
patients.
The efﬁcacy of miglustat therapy was evaluated
based on clinical examination and a compari-
son of blood GD markers measured at baseline
(before starting miglustat) and at follow-up. Analyzed
variables included plasma chitotriosidase activity
(control range: <40 nkat/L), plasma concentration
of chemokine (C-C motif) ligand 18/pulmonary and
activation-regulated (CCL18/PARC) (control range:
<100 mg/L), whole blood hemoglobin concentra-
tion (Hb) (control range: 117–153 g/L), and whole
blood platelet count (PLT) (control range: 165–387
 10
9/L). Moreover, the serum concentration of
ferritin (control range: 10–150 mg/L) and a proﬁle
of plasma immunoglobulin determined by plasma
electrophoresis and immunoﬁxation were followed
up. Assessment of the aforementioned variables
was performed at baseline and at 2, 4, 8, 12, and
15 months on miglustat therapy. Patients’ body
weight was documented at the onset of and during
miglustat therapy. AE occurring while on miglustat
were reported by patients to their physicians and
documented in patient ﬁles. The ﬁles were reviewed
for collection of relevant data. Patients provided their
informed consent.
Results
Six adult Caucasian patients with GD1 (two women,
four men), aged 21–81 years (median age 59 years),
were treated with miglustat between October
2005 and April 2011. None of these patients had a
known Jewish ancestry. All but one (83%) patient
carried at least one allele with c.1226A>G (N370S)
mutation in the GBA1 gene. One patient with a more
severe phenotype exhibited the heterozygous muta-
tions c.798C>G and c.1040T>G in the GBA1 gene by
direct DNA sequencing, which to the best of our
knowledge were never previously reported in patients
with GD (1). Three (50%) patients were splenecto-
mized earlier in their life due to GD. Patient char-
acteristics are presented in Table I.
Initiation of miglustat therapy
Three patients (pts) were previously treated with ERT
but wished to switch their treatment plan to a more
convenient oral maintenance therapy. Occupation
was a decisive factor for two frequently traveling
patients (pts 2 and 4) and one student (pt 1) when
choosing between oral versus intravenous therapy.
They all wished to decrease contacts with the health
care system to a minimum.
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and began miglustat therapy as their initial treatment
of GD. One patient (pt 6) refused the proposed ERT
and began miglustat as a more convenient oral alter-
native. Two patients (pts 3 and 5) started miglustat as
their ﬁrst-line treatment due to the worldwide supply
shortage of Cerezyme
 
during 2009–2010 which was a
consequence of viral contamination (vesivirus 2117)
of the production plant in June 2009 (10).
Efﬁcacy of miglustat therapy
During the ﬁrst 4 months of miglustat therapy, no
changes in the levels of Hb and PLT were noticed in
three patients (pts 3, 4, and 6). Hb was reduced by
12% in two patients (pts 1 and 5). In patient 1, PLT
decreased by 35% after 4 months on miglustat but still
remained within the normal range. On the contrary,
PLT in patient 5 increased by 90% after the ﬁrst
4 months of miglustat therapy, but at the time he
was experiencing a strong inﬂammatory activity due
to lung infection with Mycobacterium avium and reac-
tivation of Aspergillus fumigatus in a lung aspergilloma
(he earlier underwent partial resection of the right
lung due to aspergilloma). Of note, patient 6 suffered
from multiple myeloma of the IgG-lambda type
before starting miglustat and was diagnosed with
myelodysplastic syndrome (MDS) RAEB-2 (refrac-
tory anemia with excess of blasts type 2) 3 months
after the start of miglustat (11). Therefore, a reliable
interpretation of changes in the blood panel during
miglustat therapy with respect to GD is not possible in
his case.
One patient (pt 3) showed permanently reduced
chitotriosidase activity as early as 2 months after
the start of miglustat and a reduction of CCL18
concentration after 8 months of SRT. On the other
hand, patient 1 with a novel heterozygous GBA1
mutation and a more severe GD1 phenotype
showeddoublingofchitotriosidaseactivity4months
after miglustat initiation. An objective interpreta-
tion of chitotriosidase and CCL18 alterations on
miglustat therapy in the remaining patients is not
possible because of short follow-up or untimely
analyses. Ferritin concentrations were either stable
(pts 3 and 2) or rising (pts 1, 2, and 5) over
the period of miglustat treatment. In all but one
patient (pt 6) plasma immunoglobulin proﬁle was
unchanged by miglustat therapy in respect to poly-
clonal or monoclonal gammopathy. The effects of
miglustat therapy on visceral and skeletal disease
are not discussed herein due to the short follow-
up period of the majority of patients with respect to
these GD manifestations.
Changes in blood markers of GD and selected
variables signiﬁcant in GD observed during miglustat
therapy are given in Table II.
Adverse events during miglustat therapy
All six patients treated with miglustat suffered from at
least 2 AE, and three (50%) patients experienced at
least 4 AE (Table III). Four (66%) patients reported
diarrhea, and three (50%) patients had poor appetite.
Tremor appeared in ﬁve (83%) patients, but a more
severe form was observed only in one patient (pt 2).
Peripheral neuropathy (PN) was diagnosed in two
(33%) patients; however, multifactorial etiology was
considered in one patient (pt 6) who had a known
mild PN, vitamin B12 deﬁciency, and MGUS/mye-
loma before the start of miglustat therapy. All six
(100%) patients experienced negative weight change;
three of them (pts 1, 5, and 6) lost ‡10% of their
baseline body weight, and the remaining three
patients (pts 2, 3, and 4) lost <10% of their baseline
body weight (Table III).
Table I. Patient characteristics.
Pt Sex/Age (y)
a GBA1 gene mutations
Age at
Dx (y)
SPC/
Age (y)
Duration of
ERT (y) SMG BD
1 F/21 c.798C>G/c.1040T >G (novel mutations) 3 Y/5 4 NA Y, s
2 M/42 c.437C>T/c.1226A >G (S107L/N370S) 3 Y/12 13 NA Y, s
3 F/56 c.1226A>G/c.1226A >G (N370S/N370S) 55 N NA Y Y, rs
4 M/62 c.721G>A/c.1226A >G (G202R/N370S) 61 N 1 Y Y, s
5 M/65 c.1226A>G/RecNci (N370S/RecNci) 51 N NA Y Y, rs
6 M/81 c.1226A>G/c.1448T >C (N370S/L444P) 30 Y/32 NA NA Y, rs
aAge at start of miglustat therapy.
Pt = patient; Dx = diagnosis of Gaucher disease; SPC = splenectomy; ERT = enzyme replacement therapy; SMG = splenomegaly; BD = bone
disease (rs: radiological signs only; s: symptomatic disease); F = female; M = male; Y = yes; N = no; NA = not applicable.
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Only two out of six (33%) patients used miglustat
for longer than 12 months (pts 2 and 3), of which
only one (17%) patient was treated for more than
15 months (pt 3).
Three patients (pts 1, 4, and 5) discontinued
miglustat after 4 months of treatment due to AE
negatively impacting their quality of life (QoL). Addi-
tionally, one patient (pt 5) discontinued miglustat
due to co-morbidities (Aspergillus fumigatus and Myco-
bacterium avium infections). In one patient (pt 6),
miglustat did not inﬂuence the course of his GD after
3 months of therapy, and he agreed to ERT. Never-
theless, combination therapy ERT + SRT was con-
tinued in the hope of achieving a rapid reduction in
the bone marrow Gaucher cell burden, but shortly
afterwards transformation to acute myeloid leukemia
(AML) occurred and the patient died.
Patient 2 continued miglustat therapy for 15
months despite AE, although the compliance was
suboptimal, with the use of reduced miglustat doses
of 100 mg per day or 100 mg twice a day (b.i.d.),
upon which gradual worsening of GD status was
noticeable. He ﬁnally discontinued miglustat after
15 months.
Table II. Changes in values of selected variables observed during miglustat therapy.
Values of analyzed variables during miglustat therapy
Pt Sex/Age (y)
a Variables 0 2 m 4 m 8 m 12 m 15 m
1 F/21 B-Hb
B-PLT
S-Ferrititn
P-Chito
P-CCL18
Ig proﬁle
122
260
202
1189
428
Normal
ND 108
170
636
2392
ND
Normal
2 M/42 B-Hb
B-PLT
S-Ferritin
P-Chito
P-CCL18
Ig proﬁle
140
116
1255
ND
ND
ND
ND ND 127
95
1627
ND
ND
P IgG 19.3
117
107
ND
ND
ND
ND
127
119
2269
ND
ND
P IgG 18.6
3 F/56 B-Hb
B-PLT
S-Ferritin
P-Chito
P-CCL18
Ig proﬁle
122
68
833
1549
908
P IgM 3.2
119
66
866
446
939
P IgM 3.1
NA 125
102
932
292
323
P IgM 3.6
NA 133
104
858
323
497
P IgM 3.4
4 M/62 B-Hb
B-PLT
S-Ferritin
P-Chito
P-CCL18
Ig proﬁle
133
145
ND
3039
628
M IgM–l 1.5
ND 136
145
ND
ND
ND
M IgM–l 2.0
5 M/65 B-Hb
B-PLT
S-Ferritin
P-Chito
P-CCL18
Ig proﬁle
124
104
1239
ND‡
ND‡
P IgG 14.9
115
180
2389
ND
ND
ND
109
198
4028
986
1062
P IgG 15.2
6 M/81 B-Hb
B-PLT
S-Ferritin
P-Chito
P-CCL18
Ig proﬁle
93
20
4408
2168
ND
M IgG–l 33
84
19
4047
ND
ND
M IgG–l 25
90
12
3260
ND
ND
M IgG–l 24
91
6
ND
ND
ND
ND
aAge at start of miglustat therapy.
bThe samples were improperly transported to the laboratory.
Pt = patient; m = months on miglustat therapy; B-Hb = whole blood hemoglobin concentration (control range: 117–153 g/L); B-PLT = whole
blood platelet count (control range: 165–387  10
9/L); S-Ferritin = serum ferritin concentration (control range: 10–150 mg/L); P-Chito =
activity of plasma chitotriosidase (control range: <40 nkat/L); P-CCL18 = concentration of plasma chemokine (C-C motif) ligand 18/
pulmonary and activation-regulated (control range: <100 mg/L); ND = not determined; NA = not applicable (analyses done at the other
laboratory); Ig = immunoglobulin (g/L);
P = polyclonal;
M = monoclonal.
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therapy, and she is still using it in a full, prescribed
dose more than 20 months after the start of SRT. She
closely followed dietary restrictions for several months
as recommended; however, she had mentioned on
several occasions that to follow a Mediterranean-
like diet with restrictions of lactose and disaccharides
is quite expensive for an average person in Sweden.
This opinion was shared by three other patients. Five
(83%) patients stated that the recommended miglu-
stat administration schedule (t.i.d.) was inconvenient
for them as a form of daily life-long therapy as had
been intended originally.
Discussion
T h ee x p e r i e n c eo fm i g l u s t a tt h e r a p yf o rG D 1i nt h e
clinical practice setting has seldom been studied (9).
The present study is a single-center report based on
the experience gained with miglustat treatment in
6 out of 12 adults with GD1 (50%) controlled at
Karolinska University Hospital, which constitutes
17% of the entire Swedish GD1 population (6/35
pts). The small patient number in this retrospective
analysis may be perceived as a limitation; however,
it depends on the rarity of inherited orphan diseases.
The latter makes it often impossible to collect
large, homogeneous patient groups to be in the
same clinical situation at a single center, even over
a long period of time.
Recent data on the long-term miglustat mainte-
nance therapy of GD1 support a positive impact of
miglustat on both bone marrow and bone tissue
(8,9,12,13). Our analysis of GD markers and blood
variables important for GD has conﬁrmed the efﬁ-
cacy of miglustat in one treatment-naive patient as
well as the probable non-inferiority of miglustat in
one patient switched from ERT. An objective assess-
ment of miglustat efﬁcacy in the remaining four
patients was not possible due to the short follow-
up and the co-morbidities in two cases.
A major obstacle to successful miglustat therapy in
GD1 is the relatively high proportion of patients dis-
continuing their treatment due to the worsened QoL
(9,14). During the ﬁrst weeks or months of miglustat
therapy, a patient’s QoL is often affected by gastroin-
testinal AE (e.g. diarrhea, nausea, poor appetite, ﬂatu-
lence, and abdominal cramps), weight loss, and tremor
(14,15). Miglustat inhibits digestive disaccharidases in
the small intestinal mucosa: sucrase and maltase
strongly,andlactasemoreweakly(16).Inconsequence,
gastrointestinal AE in miglustat-treated patients are
attributed to the suboptimal hydrolysis of carbohy-
drates, subsequent osmotic diarrhea, and altered
colonic fermentation (15,16). Of note, gastrointestinal
AEtendtodecreaseinintensityandfrequencyovertime
on continued miglustat therapy. In order to minimize
weightlossandgastrointestinalAE,theproducer(Acte-
lion Pharmaceuticals) recommends that the miglustat-
treated patients should follow a low-disaccharide and
low-lactose diet, especially during the ﬁrst weeks of
therapy. The etiology of neurological side-effects asso-
ciated with miglustat treatment (e.g. tremor and PN) is
less understood. Generally, the proﬁle and the fre-
quencyofAEobservedinourmiglustat-treatedpatients
with GD1 are in line with the results of previously
reported studies (8,9,14,15). Although the patients
received dietary recommendations, all of them
Table III. Adverse events and body weight changes observed on miglustat therapy.
Pt Sex/Age (y)
a
Duration of
SRT (months) Adverse events
Absolute weight
loss on SRT
Maximal percentage
body weight change as compared
to baseline
1 F/21 4 Diarrhea, poor appetite,
weight loss
6k g –11%
2 M/42 15 Diarrhea, weight loss, tremor
(moderate), peripheral neuropathy
4k g –5%
3 F/56 20
b Weight loss, tremor (mild) 5 kg –8%
4 M/62 3 Weight loss, tremor (mild) 3 kg –4%
5 M/65 4 Diarrhea, poor appetite, weight loss,
tremor (mild)
10 kg –16%
6 M/81 8
c Diarrhea, poor appetite, weight loss
d,
tremor (mild), peripheral neuropathy
d
12 kg –18%
aAge at start of miglustat therapy.
bStill on miglustat therapy.
cThe pt died on ERT + SRT therapy due to acute myeloid leukemia.
dPossible multifactorial etiology (see comment in text).
Pt = patient; SRT = substrate reduction therapy with miglustat; F = female; M = male.
32 M. Machaczka et al.developed gastrointestinal AE affecting QoL, and as a
consequence a half of them (three of six pts) discon-
tinued miglustat treatment.
In the later period of miglustat treatment, QoL can
be affected by the persistent AE from the early phase
of therapy, new AE (e.g. PN), progression of GD due
to poor compliance or an unsatisfactory disease
response to miglustat, the busy miglustat administra-
tion schedule (t.i.d.), or issues related to dietary
restrictions aimed at diminishing gastrointestinal
AE (8,9,14). Worsened QoL can jeopardize a
patient’s compliance, leading to therapy discontinu-
ation. It should be appreciated that the producer is
making efforts to improve the compliance of
miglustat-treated patients in Sweden by supporting
dietary issues, e.g. offering miglustat patients dietary
brochures and a phone contact with a nurse in case of
any dietary questions. However, dietary restrictions
do not seem to be the ultimate solution of
QoL-related issues in miglustat patients since they
by themselves also limit QoL (dietary schedule, eco-
nomic aspects) and do not inﬂuence non-gastrointes-
tinal AE or the busy miglustat administration
schedule.
There is no doubt that miglustat is an important
alternative in the therapy of GD. An interesting fea-
ture of miglustat suggested by previous reports, par-
ticularly important in neuronopathic LSDs, is its
potential to reach the brain, where miglustat may
have beneﬁcial effects on the defective metabolism
of glycosphingolipids (17–20). However, the precise
mechanism by which miglustat might cross the
bloodbrain barrier has yet to be established.
Thisreporthighlightsthatmiglustatisadifﬁcultdrug
toadministerintheclinicalpracticesetting.Theoverall
impression is that GD1 patients experienced the nega-
tiveimpactofmiglustatontheirQoLearlyinthecourse
of their treatment, resulting in a feeling of disappoint-
ment and ultimately in the discontinuation of therapy.
Nevertheless, some possible areas of improvement can
be identiﬁed, including further support to miglustat
patients with simple and cost-effective dietary recom-
mendations,aslow-releasecapsuleformulafor‘once-a-
day administration’ instead of the current ‘t.i.d.
capsule’, and a focus on the understanding of the
pathomechanisms behind the neurological symptoms
in GD1 as well as measurements useful in their control
(21,22).Moreover,furtherstudiesareneededtoanswer
thequestionwhethercombinationtherapyERT+SRT,
ideally dose reduced and schedule modiﬁed as com-
pared to monotherapy with both treatments, may cir-
cumventobstaclesseenwithmiglustattherapyinGD1.
Such a combination therapy may offer GD patients
better disease control (by employing more than one
mechanism of action against the accumulation of
glucosylceramideincells),canbecost-effectivebyusing
reduced doses of both ERT and miglustat, and can
provide an acceptable QoL.
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